{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=verapamil+extended+release+capsule",
    "query": {
      "intervention": "verapamil extended release capsule"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T11:04:17.737Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00648401",
      "title": "Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-01",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648401"
    },
    {
      "nct_id": "NCT00647673",
      "title": "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil HCL Extended-Release Capsules 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-01",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00647673"
    },
    {
      "nct_id": "NCT00648050",
      "title": "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2006-03",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648050"
    },
    {
      "nct_id": "NCT06455319",
      "title": "Precision Administration of Anti-thymocyte Globulin With or Without Verapamil",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "verapamil extended release capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-11-12",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Gainesville, Florida",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06455319"
    },
    {
      "nct_id": "NCT03070470",
      "title": "CiPA Phase 1 ECG Biomarker Validation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced QT Prolongation",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        },
        {
          "name": "Verapamil",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Chloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dofetilide and Diltiazem",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Food and Drug Administration (FDA)",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-03-14",
      "completion_date": "2017-06-26",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070470"
    },
    {
      "nct_id": "NCT07061574",
      "title": "A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "New Onset"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "verapamil extended-release capsule",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "9 Years to 20 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-03-10",
      "completion_date": "2031-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Gainesville, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07061574"
    },
    {
      "nct_id": "NCT00649805",
      "title": "Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Verapamil Hydrochloride Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Verelan® PM Extended-Release Capsules, 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-01",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-23T11:04:17.737Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00649805"
    }
  ]
}